Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Trial Profile

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRX 34 (Primary) ; Dexamethasone
  • Indications Acute myeloid leukaemia; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Liver cancer; Liver metastases; Lung cancer; Lymphoma; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Mirna Therapeutics
  • Most Recent Events

    • 02 Apr 2020 Results assessing MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, published in the British Journal of Cancer
    • 05 Dec 2016 Results (n=47) published in the Investigational New Drugs.
    • 10 Nov 2016 According to Mirna Therapeutics media release, FDA requested a final clinical study report along with risk-benefit summary with sufficient justification for the continued development of MRX34 to remove the clinical hold.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top